QUALITY OF LIFE OF ADVANCED CERVICAL CANCER PATIENTS WITH PERCUTANEOUS NEPHROSTOMY IN HASAN SADIKIN HOSPITAL BANDUNG FROM 2018-2020
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Abstract
Objective: This study aims to assess the quality of life patients with advanced stage of cervical cancer in RSUP Dr. Hasan Sadikin Bandung from 2018-2020. Material & Methods: This is a retrospective cohort study. The data collected from woman with advanced stages of cervical cancer without history of mental health problems or recurrent cancer, and interviewed using a validated EORT CQLQ-C30 questionnaire to assess their quality of life, and functional status based Karnofsky Performance Score (KPS) and Eastern Cooperative Oncology Group (ECOG) Performance Scale. Scores are calculated into raw score and linear transformation to standardized the range of 1-100. Results: 77 women were included in this study. The average age was 47.98 ± 8.46 years. Cervical cancer predominated by stage IIIa and IV (37,66%) with bilateral nephrostomy (58.44%). This study revealed an average of 63.1 in overall health status, which means there is an improvement over patient’s symptoms resulted from the insertion of nephrostomy, and a poor quality of life with an average score of 48.3 which shows the progression of cervical cancer conditions suffered by patients. Conclusion: The use of nephrostomy in patients with advanced-stage cervical cancer (IIIa, IIIb, and IV) could help alleviate patient’s symptoms, but the progressive condition of cervical cancer has made the patient's quality of life continue to decline. This is shown by the poor quality of life score in the advanced stages of cervical cancer patients, even with nephrostomy insertion. A better understanding of the complexity of the relationship between patient’s quality of life, cervical cancer staging, and the use of nephrostomy is necessary to help cervical cancer patients deciding the best consent before any actions taken. Keywords: EORTC QLQ-C30, cervical cancer, quality of life.
##plugins.themes.bootstrap3.article.details##
EORTC QLQ-C30, cervical cancer, quality of life.
Vu M, Yu J, Awolude OA, Chuang L. Cervical cancer worldwide. Current problems in cancer. 2018;42(5):457-65.
Legianawati D, Puspitasari IM, Suwantika A, Kusumadjati A. Profil penatalaksanaan kanker serviks stadium IIB–IIIB dengan terapi radiasi dan kemoradiasi di Rumah Sakit Umum Pusat Dr. Hasan Sadikin Bandung periode tahun 2015–2017. Indonesian Journal of Clinical Pharmacy. 2019;8.
Dienstmann R, da Silva Pinto C, Pereira MT, Small IA, Ferreira CG. Palliative percutaneous nephrostomy in recurrent cervical cancer: a retrospective analysis of 50 consecutive cases. Journal of pain and symptom management. 2008;36(2):185-90.
Lapitan MC, Buckley BS. Impact of palliative urinary diversion by percutaneous nephrostomy drainage and ureteral stenting among patients with advanced cervical cancer and obstructive uropathy: a prospective cohort. The journal of obstetrics and gynaecology research. 2011;37(8):1061-70.
Liang B, Lange SS, Massad LS, Dick R, Mills KA, Hagemann AR, et al. Do gynecologic oncology patients with severely diminished renal function and urinary tract obstruction benefit from ureteral stenting or percutaneous nephrostomy? Gynecologic oncology reports. 2019;28:136-40.
Emmert C, Rassler J, Köhler U. Survival and quality of life after percutaneous nephrostomy for malignant ureteric obstruction in patients with terminal cervical cancer. Archives of gynecology and obstetrics. 1997;259(3):147-51.
Perwitasari DA, Atthobari J, Dwiprahasto I, Hakimi M, Gelderblom H, Putter H, et al. Translation and validation of EORTC QLQ-C30 into Indonesian version for cancer patients in Indonesia. Japanese journal of clinical oncology. 2011;41(4):519-29.
Flechtner H, Bottomley A. Quality of life assessment and research in the EORTC (European Organisation for Research and Treatment of Cancer). Oncologie. 2006;8(5):443–6.
Ryan M, Marlow L, Waller J. Socio-demographic correlates of cervical cancer risk factor knowledge among screening non-participants in Great Britain. Prev Med. 2019;125:1-4.
Lingappanoor S, Manupati GR, Meesala V, Yaragani P, Bachu B, Anchuri SS. Assessment of Quality of Life of Cervical Cancer Patients Using ECOG-Performance Status Scale. J Cancer Tumor Int. 2019;(September):1–8.
Mashadi IR, Gunawan A, Susanto C. Effect of percutaneous nephrostomy in late stage cervical cancer’s survival with impaired renal function. Maj Obstet Ginekol. 2018;24(2):49.
Mishra K, Desai A, Patel S, Mankad M, Dave K. Role of percutaneous nephrostomy in advanced cervical carcinoma with obstructive uropathy: a case series. Indian J Palliat Care. 2009;15(1):37-40.
Romero FR, Broglio M, Pires SR, Roca RF, Guibu IA, Perez MD. Indications for percutaneous nephrostomy in patients with obstructive uropathy due to malignant urogenital neoplasias. Int Braz J Urol. 2005;31(2):117–24.